Mesoblast talks therapy on knee osteoarthritis

Company News

Mesoblast Limited (ASX:MSB) says an injection of its MPC product candidate, resulted in an improvement in pain, function and cartilage structure in patients with post-traumatic knee injury.
 
The study results were selected for oral presentation at the 2016 Osteoarthritis Research Society International World Congress in Amsterdam.
 
The head of the Musculoskeletal unit at Monash University, Dr Flavia Cicuttini described the results as “very exciting”.
 
He also said Mesoblast’s cells may be “disease modifying and potentially slow or halt the natural history of osteoarthritis.” 
 
Mesoblast reported a net loss of $48.57 million at 31 December 2015.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?